Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease

Rahima A. Bhanji, Aldo J. Montano‐Loza, Kymberly D. Watt – 29 April 2019 – Sarcopenia is a common complication of cirrhosis and is defined as a progressive and generalized loss of skeletal muscle mass, strength, and function. Sarcopenia is associated with poor prognosis and increased mortality. How sarcopenia and muscle wasting relate to such poor outcomes requires looking beyond the overt muscle loss and at this entity as a systemic disease that affects muscles of vital organs including cardiac and respiratory muscles.

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum

Amanda Cheung, Brent A. Neuschwander‐Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group – 29 April 2019 – Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%‐2% of the population in developed nations at risk of developing NASH cirrhosis and its complications.

Subscribe to